Search Results - E. Yu. Loginova

When dactylitis is detected in a patient with psoriatic arthritis (PsA), it is necessary to use active treatment as soon as possible, since in the absence of therapy the disease progresses to joint erosion and  functional disorders. The paper considers the clinical signs and  diagnosis of PsA and no...

Full description

The paper reviews of the data available in the literature on the clinical efficacy and safety of tofacitinib (TOFA) in the treatment of psoriatic arthritis (PsA). It considers the mechanism of action of TOFA, which is mainly in the selective inhibition of signal transmission due to its effect on the...

Full description

The paper analyzes the data available in the literature on the mechanisms of action of ustekinumab (UST), a new medication to treat activepsoriatic arthritis (PsA) and psoriasis. UST is a human IgG1κ monoclonal antibody (mAb). The mechanism of action of the drug is described; UST is shown to effecti...

Full description

The novel targeted synthetic disease-modifying antirheumatic drug apremilast (AP), a phosphodiesterase 4 inhibitor, is currently used to treat psoriasis and psoriatic arthritis (PsA). AP treatment can reduce the level of proinflammatory cytokines and the activity of inflammatory changes. The article...

Full description

The paper analyzes the data available in the literature on the mechanisms of action of certolizumab pegol (CZP), a new tumor necrosis factor-α (TNF-α) inhibitor for the treatment of active psoriatic arthritis (PsA). It describes the unique molecular structure of the drug and its mechanism of action...

Full description

The article presents an analysis of literature data on the use of a new group of targeted synthetic disease-modifying antirheumatic drugs (DMARDs) Janus kinase (JAK) inhibitors – tofacitinib (TOFA) and upadacitinib (UPA) – in psoriatic arthritis (PsA). The results of randomized placebocontrolled cli...

Full description

Tumor necrosis factor-α (TNF-α) holds a central position in the pathogenesis of autoimmune inflammatory diseases of the locomotor apparatus. A separate class of drugs, namely, TNF-α inhibitors, that are effective against multicomponent diseases, such as psoriatic arthritis (PsA), is now available to...

Full description

The article presents an analysis of literature on the efficacy and safety of a new biologic disease modifying antirheumatic drug usage, the interleukin 23 inhibitor – guselkumab (GUS) – in the treatment of patients with psoriatic arthritis (PsA). Two own clinical observations of GUS therapy are desc...

Full description

Enthesitis is inflammation at the site of attachment of tendon, ligament, or joint capsule to bone, a typical symptom of psoriatic arthritis (PsA). Heel enthesitis is of the greatest clinical significance. The activation of the interleukin 23/interleukin 17 (IL-23/IL-17) axis plays a pivotal role in...

Full description

The involvement of the spine in psoriatic arthritis (PsA) is observed in a large number of cases; however, a unified approach to solving this problem has not yet been formed. Criteria for the diagnosis of psoriatic spondylitis have not been clearly defined; internationally accepted definitions for t...

Full description

Psoriatic arthritis (PsA) is a heterogeneous disease manifested by peripheral arthritis, dactylitis, spondylitis, and enthesitis. PsA is often undiagnosed by dermatovenerologists because of the difficulty in identifying a variety of clinical signs. The early diagnosis of PsA and the accurate assessm...

Full description

Patients and methods. The investigation included 103 psoriatic patients (47 men, 56 women; mean age, 44±13.69 years) with different clinical forms of Ps (mean duration, 10.7±10.2 years). Before being examined by a dermatologist, all the patients completed a Psoriasis Epidemiology Screening Tool (mPE...

Full description

The current Treat-to-target (T2T) strategy in the management of patients with psoriatic arthritis (PsA) is based on strict control over the dynamics of a patient's status and timely correction of therapy according to the presence or absence of remission or minimal disease activity (MDA) within...

Full description

Patients with psoriatic arthritis (PsA) have a higher risk of cardiovascular disease (CVD) compared with the general population. Inflammation and traditional CVD risk factors (RFs), including dyslipidemia, make a significant contribution to the development of CVD and their complications in patients...

Full description

Background. The goal of “treat-to-target” strategy (T2T) in psoriatic arthritis (PsA) is attaining remission or minimal disease activity (MDA). The benefits of T2T are shown recently in the study TICOPA and REMARCA. But prognostic factors for achievement MDA in PsA patients (pts) at the early-stage...

Full description

Remission duration and minimal disease activity (MDA) during treatment with biological agents (BA) and after their discontinuation in patients with early psoriatic arthritis (PsA) have been insufficiently studied.Objective: to study the timing of the onset and duration of remission and MDA after BA...

Full description

Background. Patients with psoriatic arthritis (PsA) have increased risk of cardiovascular diseases (CVD). Anti-tumor necrosis factor (TNF) therapy is an effective in PsA but its cardiovascular effects are poorly understood.Aim. To study the changes in carotid intima-media thickness (c-IMT), paramete...

Full description

The new Treat-to-Target (T2T) strategy in the treatment of early psoriatic arthritis (PsA) is aimed at achieving remission or low disease activity. As of now, the new biological agent ustekinumb (UST), anti-interleukin (IL) 12/23 monoclonal antibodies, was used to treat psoriasis and PsA. The paper...

Full description

The paper characterizes the basic principles of a treat-to-target (T2T) strategy for spondyloarthritis, including psoriatic arthritis (PsA). The data from observational cohort studies suggest that inadequate therapy for PsA increases the risk of structural progression. The results, obtained in the i...

Full description